Blackstone (BX) has closed a record $6.3bn in private funding for life sciences, supporting vital drug development and showing resilience in the sector.

Blackstone (BX) raised $6.3bn, marking the largest ever private funding investment round focused on life sciences. This capital will support the firm's BXLS platform, which aims to aid drug and medical technology development. Over the past year, BXLS has provided nearly $2bn in funding to companies, including $700m to MSD for an antibody-drug conjugate and $400m to Teva for inflammatory bowel diseases. The recent funding highlights ongoing investor interest in life sciences amidst challenging economic conditions.

Blackstone (BX) Closes $6.3bn Largest Life Sciences Fund Ever

AI Summary

Related News

Steakhouse Chain Recommended as Traffic Up and Beef Prices Down

MiNK Therapeutics (INKT) Begins Phase 2 Lung Injury Therapy Trial

Palvella (PALV) Phase 2 Data Shows Bleeding Reduction Results

Bread Financial (BFH) Reports Lower Loss Rates in April 2023